Chelsie Derman

A new study found an indirect effect of RA on frailty index through inflammatory cytokines.

Exactly half of the sample had previously read or applied ≥ 1 Clinical Practice Guideline in the field of fibromyalgia.

Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.

The first line treatment for restless legs syndrome—dopamine agonists—may be making a patient’s condition worse in the long-term, Winkelman told HCPLive at SLEEP 2024.

At SLEEP 2024, Kolla shared tips to help his fellow practitioners for improving patient outcomes when dealing with patients with both sleep issues and psychiatric illnesses.

Martin spoke about the barriers standing in the way of CPAP adherence in women with sleep apnea at SLEEP 2024.

At SLEEP 2024, Hartung discussed FloraWorks’ study finding patients on CBN had greater improvements in sleep quality than melatonin, but the difference was not significant.

At SLEEP 2024, Badr presented on novel treatments for central sleep apnea like phrenic nerve stimulation.

Grandner highlights the importance of focusing on insomnia treatment for sleep-related anxiety—not anxiety treatment.

During SLEEP 2024, Judite Blanc, PhD, discussed her team’s ongoing study assessing whether an education VR program improves maternal stress and sleep among women of color.

At SLEEP 2024, Broussard told HCPLive about how eating time restriction can serve as another as another dietary tool for people who are unsuccessful with other strategies.

Broussard discussed the importance of eating during the day at SLEEP 2024.

In an interview at SLEEP 2024, Brager talked about the benefits of exercise on cardiovascular health and sleep.

Parthasarathy discussed next steps for research on the relationship between sleep disturbances and immunity in an interview with HCPLive at SLEEP 2024.

Parthasarathy told HCPLive women have a weaker immune response to COVID-19 than men.

In an interview with HCPLive, Parthasarathy discussed the relationship between sleep disturbances and immune function.

In an interview with HCPLive, DelRosso spoke about the 1-year plans of the "Count on Sleep" OSA project.

At SLEEP 2024, Revana told HCPLive her thoughts on the potential of pitolisant to address excessive daytime sleepiness in Prader-Willi syndrome compared to treating narcolepsy.

Emerson previews the highly anticipated FDA advisory committee this week, and Lykos' plans for rolling out MDMA-assisted therapy in the event it is approved to treat PTSD.

A study presented as a late breaker at SLEEP 2024 found patients with COPD who have a greater mortality risk have a worse sleep quality.

Presented at SLEEP 2024 as a late-breaker, a study found a positive relationship exists between suicide severity on any day and next-day suicide severity.

A study presented at SLEEP 2024 found medicinal cannabis shows promise for improving sleep onset latency, quality, and duration in children with ASD.

A study presented at SLEEP 2024 found melatonin increased sleep latency and overall sleep quality and decreased awakenings.

A study presented at SLEEP 2024 found persistent or progressive insomnia symptoms are linked to a greater depression risk than subthreshold cases with gradual improvement.

A new study found a negative correlation between salivary rates and disease severity for patients with psoriasis.

At APA 2024, psychiatry experts shared their message to their colleagues for Mental Health Awareness Month.

A new study found patients with psoriasis and depression have increased levels of C-reaction proteins and the erythrocyte sedimentation rate.

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.

In a new study, 16% of patients with RA and 22% with PsA had sleeping issues during the last week.

Unlike approved antidepressant drugs which have warnings on their labels stating they may increase the suicide risk, NRX-101 demonstrates meaningful reductions in suicidality.